Clinical Trial Update: N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia [Phase 2]

View source ↗

Summary

An update on a Phase 2 trial investigating N-methyl-D-aspartic acid (NMDA) with cognitive remediation for schizophrenia and schizoaffective disorder; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• N-methyl-D-aspartic acid (NMDA) (N-methyl-D-aspartic acid)

Snippet

Sponsor: Nathan Kline Institute for Psychiatric Research | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: UNKNOWN